UY40612A - Piridinas sustituidas con heteroarilo y métodos de uso - Google Patents
Piridinas sustituidas con heteroarilo y métodos de usoInfo
- Publication number
- UY40612A UY40612A UY0001040612A UY40612A UY40612A UY 40612 A UY40612 A UY 40612A UY 0001040612 A UY0001040612 A UY 0001040612A UY 40612 A UY40612 A UY 40612A UY 40612 A UY40612 A UY 40612A
- Authority
- UY
- Uruguay
- Prior art keywords
- methods
- heteroaryl substituted
- substituted pyridines
- cystic fibrosis
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345315P | 2016-06-03 | 2016-06-03 | |
| UY0001037272A UY37272A (es) | 2016-06-03 | 2017-06-02 | Piridinas sustituidas con heteroarilo y métodos de uso |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY40612A true UY40612A (es) | 2024-02-15 |
Family
ID=59014678
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001040612A UY40612A (es) | 2016-06-03 | 2017-06-02 | Piridinas sustituidas con heteroarilo y métodos de uso |
| UY0001037272A UY37272A (es) | 2016-06-03 | 2017-06-02 | Piridinas sustituidas con heteroarilo y métodos de uso |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037272A UY37272A (es) | 2016-06-03 | 2017-06-02 | Piridinas sustituidas con heteroarilo y métodos de uso |
Country Status (35)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100921397B1 (ko) * | 2009-02-09 | 2009-10-14 | (주)오엠티 | 인쇄회로기판의 세척장비 및 이를 이용한 세척방법 |
| TWI735416B (zh) | 2014-10-06 | 2021-08-11 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| US10138227B2 (en) * | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
| EP3519401B1 (en) | 2016-09-30 | 2021-09-29 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| HUE052205T2 (hu) | 2016-12-09 | 2021-04-28 | Vertex Pharma | Cisztás fibrózis transzmembrán vezetõképesség szabályzó modulátora, gyógyszerészeti készítmények, kezelési eljárások és eljárás a modulátor elõállítására |
| EP3558982A1 (en) | 2016-12-20 | 2019-10-30 | AbbVie S.À.R.L. | Deuterated cftr modulators and methods of use |
| TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
| CA3066084A1 (en) | 2017-06-08 | 2018-12-13 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| US11517564B2 (en) | 2017-07-17 | 2022-12-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| KR102606188B1 (ko) | 2017-08-02 | 2023-11-23 | 버텍스 파마슈티칼스 인코포레이티드 | 피롤리딘 화합물을 제조하기 위한 공정 |
| US10988454B2 (en) | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| CA3078893A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
| CA3085006A1 (en) | 2017-12-08 | 2019-06-13 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| JP7214743B2 (ja) | 2018-02-15 | 2023-01-30 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法 |
| US10710994B2 (en) * | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| WO2019193062A1 (en) | 2018-04-03 | 2019-10-10 | Abbvie S.Á.R.L | Substituted pyrrolidines and their use |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| IT201900000687A1 (it) | 2019-01-16 | 2020-07-16 | Fondazione St Italiano Tecnologia | Composti e composizioni per il trattamento della fibrosi cistica |
| AR118555A1 (es) | 2019-04-03 | 2021-10-20 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| EP3747882A1 (en) | 2019-06-03 | 2020-12-09 | AbbVie Overseas S.à r.l. | Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| US11236067B2 (en) | 2019-07-12 | 2022-02-01 | Orphomed, Inc. | Compound for treating cystic fibrosis |
| HRP20240606T1 (hr) | 2019-08-14 | 2024-07-19 | Vertex Pharmaceuticals Incorporated | Postupak za proizvodnju modulatora za cftr |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| US11873300B2 (en) | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
| WO2021097057A1 (en) * | 2019-11-12 | 2021-05-20 | Genzyme Corporation | 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient cftr activity |
| KR20230052954A (ko) | 2020-08-20 | 2023-04-20 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 점액 과다분비를 특징으로 하는 호흡기 질환의 치료 방법 |
| IL303519A (en) | 2020-12-10 | 2023-08-01 | Vertex Pharma | Cystic fibrosis treatment methods |
| WO2022150173A1 (en) | 2021-01-06 | 2022-07-14 | AbbVie Global Enterprises Ltd. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| EP4274828A1 (en) | 2021-01-06 | 2023-11-15 | AbbVie Global Enterprises Ltd. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| CN117813006A (zh) | 2021-08-19 | 2024-04-02 | 先正达农作物保护股份公司 | 用于控制二酰胺抗性有害生物的方法及其化合物 |
| CA3267795A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | MACROCYCLICAL CFTR MODULATORS |
| CA3267788A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | COMBINATION OF MACROCYCLIC CFTR MODULATORS WITH CFTR CORRECTORS AND/OR CFTR POTENTIALIZERS |
| CN116813569B (zh) * | 2023-07-10 | 2024-07-02 | 衡阳市中心医院 | 一种抗癌药中间体的制备方法和抗癌药的制备方法 |
| WO2025186214A1 (en) | 2024-03-05 | 2025-09-12 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2561560A1 (en) * | 2004-03-30 | 2005-10-13 | The Regents Of The University Of California | Hydrazide-containing cftr inhibitor compounds and uses thereof |
| US7939558B2 (en) | 2004-06-04 | 2011-05-10 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| EP2532650A3 (en) | 2004-06-24 | 2013-11-06 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US8283351B2 (en) * | 2007-04-02 | 2012-10-09 | Institute For Oneworld Health | Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof |
| HUE025553T2 (en) | 2007-05-25 | 2016-02-29 | Vertex Pharma | CFTR modulators |
| CN101939054B (zh) | 2007-12-10 | 2014-10-29 | 诺华股份有限公司 | 有机化合物 |
| ES2422741T3 (es) | 2007-12-13 | 2013-09-13 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| CN102224141B (zh) | 2008-10-23 | 2014-10-08 | 沃泰克斯药物股份有限公司 | N-(4-(7-氮杂双环[2.2.1]庚-7-基)-2-(三氟甲基)苯基)-4-氧代-5-(三氟甲基)-1,4-二氢喹啉-3-甲酰胺的固体形式 |
| US8513282B2 (en) * | 2008-10-23 | 2013-08-20 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2010078103A1 (en) | 2008-12-30 | 2010-07-08 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2011008931A2 (en) * | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| US8247436B2 (en) * | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| BR112013007907A2 (pt) | 2010-10-08 | 2016-06-14 | N30 Pharmaceuticals Inc | novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase |
| WO2012154880A1 (en) * | 2011-05-09 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| ES2558457T3 (es) | 2011-09-16 | 2016-02-04 | Novartis Ag | Compuestos heterocíclicos para el tratamiento de fibrosis quística |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| PT2760463T (pt) | 2011-09-20 | 2019-02-27 | Univ North Carolina Chapel Hill | Regulação de canais de sódio por proteínas plunc |
| JP2016517895A (ja) | 2013-05-07 | 2016-06-20 | ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． | 嚢胞性線維症を処置するための新規化合物およびこれらの医薬組成物 |
| JP6425724B2 (ja) | 2013-08-08 | 2018-11-21 | ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． | Ｃｆｔｒモジュレーターとしてのチエノ［２，３−ｃ］ピラン |
| AU2015229188A1 (en) | 2014-03-13 | 2016-09-29 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
| CA2942387A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr actvity |
| HUE052373T2 (hu) | 2014-10-31 | 2021-04-28 | Abbvie Overseas Sarl | Szubsztituált krománok és alkalmazási eljárások |
| EP3212184B1 (en) | 2014-10-31 | 2020-04-01 | AbbVie Overseas S.à r.l. | Substituted benzotetrahydropyrans and their use |
| HK1249893A1 (zh) * | 2015-03-31 | 2018-11-16 | Vertex Pharmaceuticals (Europe) Limited | 氘代vx-661 |
| HK1253581A1 (zh) * | 2015-06-02 | 2019-06-21 | Abbvie S.A.R.L. | 经取代的吡啶及使用方法 |
| US9840513B2 (en) | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
| JP2018530557A (ja) | 2015-10-09 | 2018-10-18 | アッヴィ・エス・ア・エール・エル | 置換ピラゾロ［３，４−ｂ］ピリジン−６−カルボン酸およびこの使用 |
| JP6779992B2 (ja) | 2015-10-09 | 2020-11-04 | アッヴィ・エス・ア・エール・エル | Ｎ−スルホニル化ピラゾロ［３，４−ｂ］ピリジン−６−カルボキサミドおよび使用法 |
| EP3448842A1 (en) | 2016-04-26 | 2019-03-06 | AbbVie S.À.R.L. | Modulators of cystic fibrosis transmembrane conductance regulator protein |
| US10138227B2 (en) * | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
-
2017
- 2017-05-23 US US15/602,892 patent/US10138227B2/en active Active
- 2017-05-24 RS RS20200829A patent/RS60574B1/sr unknown
- 2017-05-24 CN CN202210433324.9A patent/CN114671864B/zh active Active
- 2017-05-24 SG SG11201808842VA patent/SG11201808842VA/en unknown
- 2017-05-24 RU RU2018138707A patent/RU2756743C2/ru active
- 2017-05-24 CN CN201780033214.0A patent/CN109311864B/zh active Active
- 2017-05-24 PL PL17728272T patent/PL3464282T3/pl unknown
- 2017-05-24 SI SI201730320T patent/SI3464282T1/sl unknown
- 2017-05-24 IL IL288243A patent/IL288243B2/en unknown
- 2017-05-24 WO PCT/IB2017/053068 patent/WO2017208115A1/en not_active Ceased
- 2017-05-24 AU AU2017273215A patent/AU2017273215B2/en active Active
- 2017-05-24 ES ES17728272T patent/ES2806873T3/es active Active
- 2017-05-24 PE PE2018003091A patent/PE20190511A1/es unknown
- 2017-05-24 KR KR1020227040379A patent/KR102719916B1/ko active Active
- 2017-05-24 KR KR1020187031861A patent/KR102469995B1/ko active Active
- 2017-05-24 PT PT177282720T patent/PT3464282T/pt unknown
- 2017-05-24 MY MYPI2018703798A patent/MY199604A/en unknown
- 2017-05-24 JP JP2018552704A patent/JP6968094B2/ja active Active
- 2017-05-24 HU HUE17728272A patent/HUE050248T2/hu unknown
- 2017-05-24 LT LTEP17728272.0T patent/LT3464282T/lt unknown
- 2017-05-24 IL IL303196A patent/IL303196B2/en unknown
- 2017-05-24 SM SM20200394T patent/SMT202000394T1/it unknown
- 2017-05-24 HR HRP20201068TT patent/HRP20201068T1/hr unknown
- 2017-05-24 CR CR20180547A patent/CR20180547A/es unknown
- 2017-05-24 MX MX2018014758A patent/MX385054B/es unknown
- 2017-05-24 DK DK17728272.0T patent/DK3464282T3/da active
- 2017-05-24 EP EP17728272.0A patent/EP3464282B1/en active Active
- 2017-05-24 RU RU2021127810A patent/RU2021127810A/ru unknown
- 2017-05-24 CA CA3022216A patent/CA3022216A1/en active Pending
- 2017-06-02 UY UY0001040612A patent/UY40612A/es not_active Application Discontinuation
- 2017-06-02 AR ARP170101516A patent/AR108672A1/es active IP Right Grant
- 2017-06-02 UY UY0001037272A patent/UY37272A/es active IP Right Grant
- 2017-06-03 TW TW113122971A patent/TW202515560A/zh unknown
- 2017-06-03 TW TW110149319A patent/TWI797926B/zh active
- 2017-06-03 TW TW106118418A patent/TWI752961B/zh active
- 2017-06-03 TW TW112108367A patent/TWI849782B/zh active
-
2018
- 2018-10-16 IL IL262415A patent/IL262415B/en unknown
- 2018-10-19 US US16/165,662 patent/US10604515B2/en active Active
- 2018-11-13 CO CONC2018/0012171A patent/CO2018012171A2/es unknown
- 2018-11-22 CL CL2018003323A patent/CL2018003323A1/es unknown
- 2018-11-26 DO DO2018000257A patent/DOP2018000257A/es unknown
- 2018-11-29 MX MX2021009322A patent/MX2021009322A/es unknown
- 2018-11-29 PH PH12018502534A patent/PH12018502534B1/en unknown
- 2018-12-13 ZA ZA2018/08423A patent/ZA201808423B/en unknown
- 2018-12-26 EC ECSENADI201894790A patent/ECSP18094790A/es unknown
-
2020
- 2020-07-14 CY CY20201100646T patent/CY1124031T1/el unknown
-
2021
- 2021-10-25 JP JP2021173679A patent/JP7392211B2/ja active Active
- 2021-12-07 AU AU2021282409A patent/AU2021282409B2/en not_active Expired - Fee Related
-
2022
- 2022-02-18 AR ARP220100344A patent/AR124916A2/es unknown
-
2023
- 2023-03-27 JP JP2023049450A patent/JP7622122B2/ja active Active
-
2024
- 2024-04-16 AU AU2024202468A patent/AU2024202468A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY40612A (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
| CO2017012566A2 (es) | Piridinas sustituidas y método de uso | |
| ECSP20021913A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
| CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
| MX380092B (es) | Tratamiento de la osteoartritis. | |
| CR20160119A (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística | |
| MX2018007774A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| UY35971A (es) | Macrociclos con grupos p2? aromáticos como inhibidores del factor xia | |
| MX375970B (es) | Compuestos de triazolopirimidina y usos de los mismos. | |
| UY36244A (es) | Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen | |
| MX2015015412A (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica. | |
| UY34960A (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| UY35972A (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| EA201691272A1 (ru) | Тетрагидропиридопиразины в качестве модуляторов gpr6 | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| DOP2020000118A (es) | Proceso para la preparación de derivados de quinolina | |
| BR112016018418A2 (pt) | Composto, uso do mesmo, e composição farmacêutica | |
| EA201700356A1 (ru) | Новые циклопропанбензофуранилпиридопиразиндионы | |
| MX2018016339A (es) | Compuestos heterociclicos antiinfecciosos y sus usos. | |
| EA201692090A1 (ru) | Полициклические активаторы herg | |
| EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RDES | Application refused |
Effective date: 20250516 |